Kalaris Therapeutics Appoints Liisa Bayko as CFO
Kalaris Therapeutics has appointed Liisa Bayko as its new Chief Financial Officer, bringing over two decades of biotechnology finance and capital markets experience. The stock fell by 5.25% to $4.15 in pre-market trading following the announcement.
Topics: Biotechnology CFO Appointment